OMCL vs. HIMS: Which Stock Should Value Investors Buy Now?
Investors looking for stocks in the Medical Info Systems sector might want to consider either Omnicell (OMCL) or Hims & Hers Health, Inc. (HIMS). But which of these two stocks offers value investors a better bang for their buck right now?
Omnicell, Inc. (OMCL) Q3 2025 Earnings Call Transcript
Omnicell, Inc. ( OMCL ) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Kathleen Nemeth - Senior Vice President of Investor Relations Randall Lipps - Founder, Executive Chairman, President & CEO H. Radford - Executive VP & CFO Conference Call Participants Jessica Tassan - Piper Sandler & Co., Research Division Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Stanislav Berenshteyn - Wells Fargo Securities, LLC, Research Division David Larsen - BTIG, LLC, Research Division William Sutherland - The Benchmark Company, LLC, Research Division Scott Schoenhaus - KeyBanc Capital Markets Inc., Research Division Eugene Mannheimer - Prime Executions, Inc., Research Division Allen Lutz - BofA Securities, Research Division Presentation Operator Thank you for standing by.
Earnings Preview: Omnicell (OMCL) Q3 Earnings Expected to Decline
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Reasons to Add Omnicell Stock to Your Portfolio Right Now
OMCL's expanding SaaS portfolio, overseas growth plans, and solid balance sheet position it for sustained momentum despite rising competition.
OMCL or HIMS: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical Info Systems stocks have likely encountered both Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two stocks presents investors with the better value opportunity right now?
Earnings Estimates Rising for Omnicell (OMCL): Will It Gain?
Omnicell (OMCL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Wall Street Analysts Believe Omnicell (OMCL) Could Rally 34.18%: Here's is How to Trade
The consensus price target hints at a 34.2% upside potential for Omnicell (OMCL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Omnicell, Inc. (OMCL) Q2 2025 Earnings Conference Call Transcript
Omnicell, Inc. (NASDAQ:OMCL ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Kathleen Nemeth - Senior Vice President of Investor Relations Nchacha E. Etta - Executive VP & CFO Randall A.
Wall Street Analysts See a 44.47% Upside in Omnicell (OMCL): Can the Stock Really Move This High?
The mean of analysts' price targets for Omnicell (OMCL) points to a 44.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Omnicell (OMCL) Beats Q2 Earnings and Revenue Estimates
Omnicell (OMCL) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.51 per share a year ago.
OMCL vs. DOCS: Which Stock Is the Better Value Option?
Investors with an interest in Medical Info Systems stocks have likely encountered both Omnicell (OMCL) and Doximity (DOCS). But which of these two stocks offers value investors a better bang for their buck right now?
Analysts Estimate Omnicell (OMCL) to Report a Decline in Earnings: What to Look Out for
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
